Cozzi-Lepri, A; Zangerle, R; Machala, L; Zilmer, K; Ristola, M; Pradier, C; Kirk, O; Sambatakou, H; Fätkenheuer, G; Yust, I; Schmid, P; Gottfredsson, M; Khromova, I; Jilich, D; Flisiak, R; Smidt, J; Rozentale, B; Radoi, R; Losso, M H; Lundgren, J D; Mocroft, A; EuroSIDA Study Group (2018). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Medicine, 19(2):102-117.
Vrouenraets, S M E; Wit, F W N M; Garcia, E Fernandez; Huber, M; Brinkman, K; Moyle, G; Domingo, P; Tarr, P E; Podzamczer, D; Ristola, M; Gatell, J M; Livrozet, J M; Furrer, H; Reiss, P (2012). Longer prior exposure to zidovudine/lamivudine-containing combination antiretroviral therapy, age, and male gender are each associated with reduced subcutaneous adipose tissue. HIV Clinical Trials, 13(2):103-110.
Kowalska, J D; Mocroft, A; Ledergerber, B; Florence, E; Ristola, M; Begovac, J; Sambatakou, H; Pedersen, C; Lundgren, J D; Kirk, O (2011). A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study. HIV Clinical Trials, 12(2):109-117.